(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.72%) $79.56
(5.53%) $2.31
(1.27%) $2 351.70
(3.48%) $28.56
(0.85%) $993.00
(-0.28%) $0.927
(-0.37%) $10.85
(-0.21%) $0.798
(0.88%) $92.55
5 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 5.93%
Live Chart Being Loaded With Signals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy...
Stats | |
---|---|
本日の出来高 | 770 537 |
平均出来高 | 752 134 |
時価総額 | 1.47B |
EPS | $0 ( 2024-05-08 ) |
次の収益日 | ( $-0.970 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.89 |
ATR14 | $0.0360 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Jarrett Jennifer | Sell | 11 551 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 12 153 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 1 296 | Common Stock |
2024-02-26 | Jarrett Jennifer | Sell | 24 555 | Common Stock |
2024-02-27 | Jarrett Jennifer | Sell | 34 070 | Common Stock |
INSIDER POWER |
---|
95.54 |
Last 100 transactions |
Buy: 19 279 293 | Sell: 529 920 |
ボリューム 相関
Arcus Biosciences Inc 相関
10 最も正の相関 | |
---|---|
MCS | 0.861 |
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Arcus Biosciences Inc 相関 - 通貨/商品
Arcus Biosciences Inc 財務諸表
Annual | 2023 |
収益: | $117.00M |
総利益: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2023 |
収益: | $117.00M |
総利益: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2022 |
収益: | $112.00M |
総利益: | $98.00M (87.50 %) |
EPS: | $-3.71 |
FY | 2021 |
収益: | $382.88M |
総利益: | $382.88M (100.00 %) |
EPS: | $0.964 |
Financial Reports:
No articles found.
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。